These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 17287429

  • 1. Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice.
    Christensen EI, Zhou Q, Sørensen SS, Rasmussen AK, Jacobsen C, Feldt-Rasmussen U, Nielsen R.
    J Am Soc Nephrol; 2007 Mar; 18(3):698-706. PubMed ID: 17287429
    [Abstract] [Full Text] [Related]

  • 2. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
    Takenaka T, Murray GJ, Qin G, Quirk JM, Ohshima T, Qasba P, Clark K, Kulkarni AB, Brady RO, Medin JA.
    Proc Natl Acad Sci U S A; 2000 Jun 20; 97(13):7515-20. PubMed ID: 10840053
    [Abstract] [Full Text] [Related]

  • 3. Kidney transplantation and enzyme alpha-galactosidase A therapy in patient with Fabry disease: a case report.
    Dziemianko I, Jezior D, Boratyńska M, Patrzałek D, Kuźniar J, Szyber P, Klinger M.
    Transplant Proc; 2007 Nov 20; 39(9):2925-7. PubMed ID: 18022018
    [Abstract] [Full Text] [Related]

  • 4. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
    Jung SC, Han IP, Limaye A, Xu R, Gelderman MP, Zerfas P, Tirumalai K, Murray GJ, During MJ, Brady RO, Qasba P.
    Proc Natl Acad Sci U S A; 2001 Feb 27; 98(5):2676-81. PubMed ID: 11226298
    [Abstract] [Full Text] [Related]

  • 5. An in vitro model of Fabry disease.
    Shu L, Murphy HS, Cooling L, Shayman JA.
    J Am Soc Nephrol; 2005 Sep 27; 16(9):2636-45. PubMed ID: 16033856
    [Abstract] [Full Text] [Related]

  • 6. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer.
    Takahashi H, Hirai Y, Migita M, Seino Y, Fukuda Y, Sakuraba H, Kase R, Kobayashi T, Hashimoto Y, Shimada T.
    Proc Natl Acad Sci U S A; 2002 Oct 15; 99(21):13777-82. PubMed ID: 12370426
    [Abstract] [Full Text] [Related]

  • 7. In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line.
    Naganawa Y, Ohsugi K, Kase R, Date I, Sakuraba H, Sakuragawa N.
    Cell Transplant; 2002 Oct 15; 11(4):325-9. PubMed ID: 12162373
    [Abstract] [Full Text] [Related]

  • 8. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells.
    Yoshimitsu M, Higuchi K, Ramsubir S, Nonaka T, Rasaiah VI, Siatskas C, Liang SB, Murray GJ, Brady RO, Medin JA.
    Gene Ther; 2007 Feb 15; 14(3):256-65. PubMed ID: 16929352
    [Abstract] [Full Text] [Related]

  • 9. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
    Przybylska M, Wu IH, Zhao H, Ziegler RJ, Tousignant JD, Desnick RJ, Scheule RK, Cheng SH, Yew NS.
    J Gene Med; 2004 Jan 15; 6(1):85-92. PubMed ID: 14716680
    [Abstract] [Full Text] [Related]

  • 10. Preselective gene therapy for Fabry disease.
    Qin G, Takenaka T, Telsch K, Kelley L, Howard T, Levade T, Deans R, Howard BH, Malech HL, Brady RO, Medin JA.
    Proc Natl Acad Sci U S A; 2001 Mar 13; 98(6):3428-33. PubMed ID: 11248095
    [Abstract] [Full Text] [Related]

  • 11. Enzymatic corrections for cells derived from Fabry disease patients by a recombinant adenovirus vector.
    Ohsugi K, Kobayashi K, Itoh K, Sakuraba H, Sakuragawa N.
    J Hum Genet; 2000 Mar 13; 45(1):1-5. PubMed ID: 10697955
    [Abstract] [Full Text] [Related]

  • 12. Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease.
    Ishii S, Chang HH, Yoshioka H, Shimada T, Mannen K, Higuchi Y, Taguchi A, Fan JQ.
    J Pharmacol Exp Ther; 2009 Mar 13; 328(3):723-31. PubMed ID: 19106170
    [Abstract] [Full Text] [Related]

  • 13. Non-viral, integrin-mediated gene transfer into fibroblasts from patients with lysosomal storage diseases.
    Estruch EJ, Hart SL, Kinnon C, Winchester BG.
    J Gene Med; 2001 Mar 13; 3(5):488-97. PubMed ID: 11601762
    [Abstract] [Full Text] [Related]

  • 14. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor.
    Fan JQ, Ishii S, Asano N, Suzuki Y.
    Nat Med; 1999 Jan 13; 5(1):112-5. PubMed ID: 9883849
    [Abstract] [Full Text] [Related]

  • 15. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
    Prabakaran T, Birn H, Bibby BM, Regeniter A, Sørensen SS, Feldt-Rasmussen U, Nielsen R, Christensen EI.
    Nephrol Dial Transplant; 2014 Mar 13; 29(3):619-25. PubMed ID: 24215016
    [Abstract] [Full Text] [Related]

  • 16. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
    Ziegler RJ, Yew NS, Li C, Cherry M, Berthelette P, Romanczuk H, Ioannou YA, Zeidner KM, Desnick RJ, Cheng SH.
    Hum Gene Ther; 1999 Jul 01; 10(10):1667-82. PubMed ID: 10428212
    [Abstract] [Full Text] [Related]

  • 17. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
    Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O'Callaghan M.
    Kidney Int; 2002 Dec 01; 62(6):1933-46. PubMed ID: 12427118
    [Abstract] [Full Text] [Related]

  • 18. 4-Phenylbutyrate rescues trafficking incompetent mutant alpha-galactosidase A without restoring its functionality.
    Yam GH, Roth J, Zuber C.
    Biochem Biophys Res Commun; 2007 Aug 24; 360(2):375-80. PubMed ID: 17592721
    [Abstract] [Full Text] [Related]

  • 19. Purification and characterization of human alpha-galactosidase A expressed in insect cells using a baculovirus vector.
    Chen Y, Jin M, Goodrich L, Smith G, Coppola G, Calhoun DH.
    Protein Expr Purif; 2000 Nov 24; 20(2):228-36. PubMed ID: 11049747
    [Abstract] [Full Text] [Related]

  • 20. [Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations].
    Germain DP.
    J Soc Biol; 2002 Nov 24; 196(2):183-90. PubMed ID: 12360747
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.